Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. - Wikidata - awgldk - TriplyDB

Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.

Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.

http://www.wikidata.org/entity/Q40071292

about

Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer Immunotherapy for Gastroesophageal Cancer Immunological battlefield in gastric cancer and role of immunotherapies A unified model of the hierarchical and stochastic theories of gastric cancer.Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer.Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma.Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer.Immunotherapy for gastric cancers: emerging role and future perspectives.Gastric adenocarcinoma.CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer.Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development.Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers.Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis.Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy.Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry.Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Ca Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients.Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer.Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review.Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.Enhanced gastric cancer growth potential of mesenchymal stem cells derived from gastric cancer tissues educated by CD4(+) T cells.Histopathological and Immunophenotypic Features of Ipilimumab-Associated Colitis Compared to Ulcerative Colitis.Gastric cancer: Basic aspects.Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers.Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients.The Peripheral and Intratumoral Immune Cell Landscape in Cancer Patients: A Proxy for Tumor Biology and a Tool for Outcome Prediction.A proteomic landscape of diffuse-type gastric cancer.Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability.Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.The Progress of T Cell Immunity Related to Prognosis in Gastric Cancer.

P2860

Q26740208-1DA29EE5-667E-4303-971E-3D342DBA2CBC Q28069873-6CA53721-3F11-4265-907A-EE78B938AAF4 Q28071836-B9F6AB6B-2CDA-40EC-A9B7-5E3516E74C11 Q33577624-2A603B84-EC73-44D4-BE7A-C698AF970D0C Q33688662-FCBAC4ED-830E-480C-B7BC-D6EB6ACDEC94 Q33888982-EA56E055-ADAB-4297-8539-48CD75081C57 Q34522172-8D7878A2-9EED-4C9D-BABB-EBF67CDE6B9C Q36358014-0A05F5C4-8FA6-49CE-B8EA-4D26099AEF6E Q37362803-017F7202-E189-467C-8013-63E21020311F Q37520133-3DEDD1E4-BE0D-46B7-9E00-AC669D7CF3D6 Q38695286-BCC3D1E7-F83C-44EF-92D7-BF76691157EB Q38710450-469E553E-C80F-42DD-813C-163D4A157753 Q38730936-943C744D-CD22-4A56-9BB3-F60F0FF1F0C9 Q38738652-50FFD40E-A0A2-4949-BE2C-407D2B3BE9EA Q39343374-15F2D09C-7A2E-463A-841F-7C5AED5FFC5E Q40336060-1188556B-A0C6-49A5-B98E-A8445F978F83 Q41110505-9F3A2934-9493-445D-8BD0-0D9DAB14BE23 Q41169821-E9267F05-588B-448E-A13D-FEE9EC36B940 Q41708934-6EDA6FD0-12C0-47DD-AC95-03844724EDE3 Q41709065-30053DBE-EE0D-4545-82A2-5737366081D0 Q41924371-7978543A-908D-4678-959D-D1DBA0184800 Q41967898-676176B1-890F-42A7-9E12-4227DDAB50A7 Q42376660-AD2CAFA3-571C-49E5-B695-0575B23CA306 Q46540302-F73EEA67-2DF3-48EE-AFFE-ACB54B0068E7 Q47094138-866EBA16-64EB-48D9-A39B-8B32422FDC79 Q47137632-4DF1400C-50A1-44EA-8E5E-29DDDAAFA3A2 Q47139741-C4BF960A-8DD4-49B7-AFD6-5F02F57E65CD Q47864236-A3491E8E-A34F-4E89-9381-94AF99A23173 Q48150040-3CC478AB-D3D5-408B-96A3-ADF3F5C7CE6B Q49719593-36C1B712-6857-4F58-9B4D-518F0814C22D Q50168318-62318AA2-933C-477B-8B2E-78BFC60549D6 Q50288120-512F50B6-223A-4D0E-94CE-F53A5762E1A9 Q52643527-7897C5D4-13DE-445C-ADD3-F8DC56BFA250 Q52649601-623F9105-DB8C-409B-9CBC-F423E9A5ECEE Q52679182-65BD29CD-B1B7-4AEC-A73E-77D621D67274 Q52727768-53477EF9-1D13-4C94-B9D2-0E01B07FECD9 Q52733772-3B2DF257-4D66-4506-9606-9036A40B190B Q54238201-DA300F55-A452-4E2D-81DF-51D9FF53CE2B Q54989184-78A1E12C-2AA0-4AC6-8161-93E28694B4B3 Q55007801-2577E785-AFA0-4A01-9C9D-8CCAF68E54C9

P2860

Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.

http://www.wikidata.org/entity/Q40071292

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Patterns of PD-L1 expression a ...... and associated immune stroma.

@en

type

label

Patterns of PD-L1 expression a ...... and associated immune stroma.

@en

prefLabel

Patterns of PD-L1 expression a ...... and associated immune stroma.

@en

P1433

Q40071292-4BF7AADB-DEB9-441C-8F22-EE32DD9D85A2

P1476

Q40071292-690BCBBB-786B-4A55-8503-D7255DC5B353

P2093

Q40071292-0C5ADC2E-4273-4765-B90F-C533C32488E8

Q40071292-19A36667-A1B0-4664-9FF9-C018BFDEDCAB

Q40071292-23A2C9FE-1696-46FD-8ACB-6343656A6723

Q40071292-450D671D-0FF5-4A64-9766-5ABDF3B89C3B

Q40071292-49DBD1C6-9DF8-4E67-90F4-E35BB2B15C98

Q40071292-72EDACAA-6C94-4FE0-A449-80D4EDFF0C7F

Q40071292-987369BD-342E-4C2A-A111-EB87829F226C

Q40071292-C93AC7D1-73B7-42D9-853E-DABC19234791

Q40071292-CAD68471-39FA-4E06-8D52-5865A7B50829

Q40071292-D1BB95AF-6B68-41A4-9028-55ABC2B6BFFF

P2860

Q40071292-038629A7-088E-4ABA-AC4D-F747D866A7DF

Q40071292-08C6B7A0-CF27-415F-ABDB-2598439B8502

Q40071292-09063A32-15E1-4AAD-9EF0-01CF9399DE8A

Q40071292-16DD56C4-46AB-4EBB-9DB1-D704FE109A77

Q40071292-179D37FB-03D1-4001-8D6B-9B1F22789C31

Q40071292-23ED7818-4FD1-4C57-B34E-1AD4FCAAB217

Q40071292-25A71A33-0E97-4C74-ACAD-D013C23C1F61

Q40071292-29ED5883-FAFA-49E3-8606-F56D69CB899B

Q40071292-30CC6ED5-20A1-4515-8C20-3BB34BDC89E9

Q40071292-4C232524-35C2-4190-93B2-98D5F17928B3

P304

Q40071292-9A1129F7-BAA4-4CCD-82B8-C8CB5D04BECD

P31

Q40071292-25394633-3246-4056-9A1C-5E259F565F23

P356

Q40071292-5C0FE855-5180-46E6-BE2F-F3D829F8A0F3

P407

Q40071292-30B3ABC7-DEC8-4C9A-98E8-A3DA98F53A28

P433

Q40071292-9B2D3EB9-7FD0-4D5A-8CC2-522D738E6C8C

P478

Q40071292-3F539833-789E-4897-BA31-D7E967CCF662

P50

Q40071292-B66076DB-A101-4AE5-912E-731C35E23941

P577

Q40071292-86CCEF2B-9092-4176-9ED3-7FD7F6EE92AA

P5875

Q40071292-36D942EA-DDDD-4485-BCF9-B6A882F1174F

P698

Q40071292-262012B3-22D8-4012-B7A5-5BF8DCA96CBE

P921

Q40071292-24669DB6-4FA7-488C-8BD4-50183202BBF8

P932

Q40071292-923D6203-256A-4C96-A6B0-62A0045F64D6

P356

GUTJNL-2015-310839

P1433

P1476

Patterns of PD-L1 expression a ...... and associated immune stroma.

@en

P2093

Adrian Murphy

http://www.w3.org/2001/XMLSchema#string

Eihab Abdelfatah

http://www.w3.org/2001/XMLSchema#string

Elizabeth D Thompson

http://www.w3.org/2001/XMLSchema#string

Janis M Taube

http://www.w3.org/2001/XMLSchema#string

Marianna Zahurak

http://www.w3.org/2001/XMLSchema#string

Mark Duncan

http://www.w3.org/2001/XMLSchema#string

Nathan Cuka

http://www.w3.org/2001/XMLSchema#string

Nita Ahuja

http://www.w3.org/2001/XMLSchema#string

Robert A Anders

http://www.w3.org/2001/XMLSchema#string

Ronan J Kelly

http://www.w3.org/2001/XMLSchema#string

P2860

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

Comprehensive molecular characterization of gastric adenocarcinoma

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

P304

794-801

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUTJNL-2015-310839

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

291692438

http://www.w3.org/2001/XMLSchema#string

P698

26801886

http://www.w3.org/2001/XMLSchema#string

P921

P932

4958028

http://www.w3.org/2001/XMLSchema#string